Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
Journal Article
|Research
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health
BACKGROUND
New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...
Journal Article
|Research
2020-05-02 • Journal of Viral Hepatitis
2020-05-02 • Journal of Viral Hepatitis
Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF+DCV) facilitate simplified models of care for hepatitis C virus (HCV). ...
Journal Article
|Research
2021-03-19 • Lancet Gastroenterology and Hepatology
2021-03-19 • Lancet Gastroenterology and Hepatology
BACKGROUND
Direct-acting antiviral treatment for hepatitis C virus (HCV) has provided the opportunity for simplified models of care delivered in decentralised settings by non-special...
Direct-acting antiviral treatment for hepatitis C virus (HCV) has provided the opportunity for simplified models of care delivered in decentralised settings by non-special...